Contraception Language in Informed Consent Forms: A Survey of Biopharmaceutical Companies

Drug Information Journal

Volumn 46, Issue 3, 2012, Pages 329-335

  Ng, Eric W ^a   Chiruvolu, Padmaja ^a   Levy, Gweneth F ^a   Allan, Brent R ^a   Wyszynski, Diego F ^a  

^a AMGEN INC   (United States)

Author keywords

clinical trial; contraception; drug industry; informed consent; pregnancy

Indexed keywords

SPERMICIDAL AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); CONDOM; CONTRACEPTION; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; FEMALE; FEMALE STERILIZATION; HORMONAL CONTRACEPTION; HUMAN; INFORMED CONSENT; INTRAUTERINE CONTRACEPTIVE DEVICE; LACTATION; LANGUAGE; MALE; MALE STERILIZATION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL;

EID: 84864808870     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/0092861512438747     Document Type: Article

References (17)

1. Clarification of Contraceptive Wording in Clinical Trials Conducted in the UK. London, UK: Medicines and Healthcare Products Regulatory Agency; 2010:.
2. Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, M3(R2). Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers & Associations; 2009:.
3. Nolan MT,Pressman EK,Starklauf BL, et al.Consent documents, reproductive issues, and the inclusion of women in clinical trials.Acad Med. 1999;74 (3): 275-281.
4. Cain J,Lowell J,Thorndyke L, et al.Contraceptive requirements for clinical research.Obstet Gynecol. 2000;95 (6 pt 1): 861-866.
5. Birth Control Guide. Washington, DC: US Food and Drug Administration; 2010:.
6. Selected Practice Recommendations for Contraceptive Use. Basel, Switzerland: World Health Organization; 2004:.
7. Friedler G.Paternal exposures: impact on reproductive and developmental outcome: an overview.Pharmacol Biochem Behav. 1996;55 (4): 691-700.
8. Trasler JM,Doerksen T.Teratogen update: paternal exposures-reproductive risks.Teratology. 1999;60 (3): 161-172.
9. De Santis M,Cesari E,Cavaliere A, et al.Paternal exposure and counselling: experience of a Teratology Information Service.Reprod Toxicol. 2008;26 (1): 42-46.
10. Klemmt L,Scialli AR.The transport of chemicals in semen.Birth Defects Res B Dev Reprod Toxicol. 2005;74 (2): 119-131.
11. Beran RG.The ethics of excluding women who become pregnant while participating in clinical trials of anti-epileptic medications.Seizure. 2006;15 (8): 563-570.
12. Guideline on the Exposure to Medicinal Products During Pregnancy: Need for Post-Authorisation Data. London, UK: European Medicines Agency; 2005:.
13. Reviewer Guidance Evaluating the Risks of Drug Exposure in Human Pregnancies. Washington, DC: US Food and Drug Administration; 2005:.
14. Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs, E2C(R1). Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers & Associations; 2005:.
15. Finer LB,Henshaw SK.Disparities in rates of unintended pregnancy in the United States, 1994 and 2001.Perspect Sex Reprod Health. 2006;38 (2): 90-96.
16. Shaping the Future of Pharmacovigilance. New York, NY: WCI Group; 2010:.
17. Uhl K,Miller MA,Kennedy DL.Complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials.J Womens Health (Larchmt). 2004;13 (6): 743-744.